Laverdia becomes available for dogs with lymphoma

Dechra has officially brought Laverdia to market in the U.S., turning a long-discussed oncology option into a purchasable product for clinics treating dogs with lymphoma. The September 23, 2026 availability announcement follows the FDA's January 16, 2026 notice that Laverdia, or verdinexor tablets, had received full approval as the first oral treatment approved for canine lymphoma. (dechra-us.com)

That full approval matters because Laverdia had been on the market in a different regulatory posture for years. The FDA first granted conditional approval in January 2021 through the Minor Use/Minor Species pathway, which is available for diseases affecting relatively small patient populations. After four annual renewals, the sponsor generated the effectiveness data needed for full approval. Dechra had acquired worldwide rights to verdinexor from Anivive in January 2022, setting up the current launch under Dechra's commercial organization. (fda.gov)

In practical terms, Laverdia gives veterinarians a prescription oral option that pet parents can administer at home. According to the FDA freedom of information summary, the labeled regimen starts at 1.25 mg/kg orally twice weekly, with at least 72 hours between doses, and may increase after two weeks to 1.5 mg/kg if tolerated; doses should be given with food or immediately after a meal. The approval covers treatment of lymphoma in dogs, and Dechra says the product is positioned for use across B-cell and T-cell disease, including immediately after diagnosis, while a family considers chemotherapy, after relapse, or when standard multi-agent protocols are not the preferred route. (animaldrugsatfda.fda.gov)

The evidence package behind the approval was larger than the earlier conditional pathway. FDA and DailyMed materials describe a randomized, masked, controlled, multicenter field study in 160 client-owned dogs, with time to progression as the primary endpoint. In the full-approval summary, the evaluable population included 106 dogs in the Laverdia group and 28 controls. The drug's mechanism is also distinct from conventional cytotoxic chemotherapy: verdinexor is a selective inhibitor of nuclear export that blocks XPO1/CRM1-mediated transport, allowing tumor suppressor and growth-regulatory proteins to remain in the nucleus and continue their normal activity. (animaldrugsatfda.fda.gov)

Industry and clinical reaction has centered on access and use in primary care. In Dechra's launch announcement, board-certified oncologist Craig A. Clifford said he sees Laverdia as an important primary care option for dogs whose families want meaningful treatment but may not pursue standard chemotherapy, and he added that his specialty practice has also used it in patients whose lymphoma has not responded to standard therapy. AAHA has made a similar, if more measured, point: oral verdinexor can be considered in general practice, is easier to administer, and may help some dogs live longer than prednisone alone, though it is not as efficacious as multi-agent or single-agent chemotherapy protocols. (dechra-us.com)

Why it matters: This launch could reshape the early conversation after a lymphoma diagnosis, especially outside referral centers. Dechra says only about 20% of dogs with lymphoma receive chemotherapy, suggesting a large gap between diagnosis and active treatment. For general practitioners, Laverdia may function less as a replacement for gold-standard oncology care than as a bridge, a fallback, or a more accessible option when geography, finances, caregiver bandwidth, or treatment goals rule out IV protocols. That said, the convenience comes with real clinical and operational obligations: the drug is prescription-only, requires monitoring for adverse events, and carries client safety instructions around chemotherapy-resistant gloves and handling bodily fluids during treatment and for three days after the final dose. (dechra-us.com)

What to watch: The next key question is adoption, specifically whether GPs use Laverdia mainly as a first-step therapy after diagnosis, as a bridge to oncology referral, or in relapse and palliative settings. Watch, too, for post-launch education from Dechra and oncology groups on case selection, monitoring, and how practices should frame expectations against established CHOP-based outcomes, because the commercial launch expands access, but it doesn't erase the efficacy gap between oral targeted therapy and standard combination chemotherapy. That last point is an inference based on the label, AAHA commentary, and Dechra's stated positioning. (dechra-us.com)